Literature DB >> 16652387

Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.

M Tandy Sutton1, Melissa Yingling, Ash Vyas, Humphrey Atiemo, Andrew Borkowski, Stephen C Jacobs, Natasha Kyprianou.   

Abstract

BACKGROUND: This study investigated the effects of finasteride, a 5alpha-reductase inhibitor, clinically used for the treatment of benign prostatic hyperplasia (BPH) on prostate tumor vascularity, apoptosis, and cell adhesion in situ and in vitro.
METHODS: Prostate specimens from BPH patients treated with finasteride for 1-12 months (n = 13), or without finasteride treatment (n = 14), were evaluated for apoptosis (TUNEL assay), microvessel density (Factor VIII), and prostate specific antigen (PSA) immunoreactivity. In vitro, the effect of finasteride was investigated in benign prostate cells, BPH-1, and its tumorigenic derivatives, CAFTD-01 and CAFTD-03, using Hoechst staining and cell adhesion assays.
RESULTS: A significant increase in the apoptotic index, and reduced microvessel density and PSA expression were detected in prostates from finasteride-treated patients, compared to controls (P < 0.01). In vitro finasteride led to a significant decrease in prostate epithelial cell adhesion (P < 0.05).
CONCLUSIONS: Finasteride can induce prostate apoptosis and reduce tissue vascularity by inhibiting epithelial cell adhesion. This evidence supports that finasteride has apoptotic and anti-angiogenic effects against benign and malignant prostate. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652387     DOI: 10.1002/pros.20444

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Magnetic Resonance Imaging and Molecular Characterization of a Hormone-Mediated Murine Model of Prostate Enlargement and Bladder Outlet Obstruction.

Authors:  Erin M McAuley; Devkumar Mustafi; Brian W Simons; Rebecca Valek; Marta Zamora; Erica Markiewicz; Sophia Lamperis; Anthony Williams; Brian B Roman; Chad Vezina; Greg Karczmar; Aytekin Oto; Donald J Vander Griend
Journal:  Am J Pathol       Date:  2017-08-18       Impact factor: 4.307

Review 2.  Combination 5-alpha-reductase inhibitors and alpha-blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Joseph C Clarke; Harry Clarke
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

3.  Banana Flower Extract Suppresses Benign Prostatic Hyperplasia by Regulating the Inflammatory Response and Inducing G1 Cell-cycle Arrest.

Authors:  Liang-Chih Liu; Yung-Hsiang Lin; Ying-Chao Lin; Chi-Tang Ho; Chao-Ming Hung; Tzong-DER Way; DA-Tian Bau
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

Review 4.  Is There a Role for Preoperative 5 Alpha Reductase Inhibitors in Reducing Prostate Vascularity and Blood Loss?

Authors:  Matthew Bruha; Charles Welliver
Journal:  Curr Urol Rep       Date:  2017-10       Impact factor: 3.092

5.  Should Finasteride Be Routinely Given Preoperatively for TURP?

Authors:  O M Aboumarzouk; M Z Aslam; A Wedderburn; K Turner; O Hughes; H G Kynaston
Journal:  ISRN Urol       Date:  2013-07-29

Review 6.  Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.

Authors:  Letteria Minutoli; Mariagrazia Rinaldi; Herbert Marini; Natasha Irrera; Giovanni Crea; Cesare Lorenzini; Domenico Puzzolo; Andrea Valenti; Antonina Pisani; Elena B Adamo; Domenica Altavilla; Francesco Squadrito; Antonio Micali
Journal:  Int J Mol Sci       Date:  2016-08-11       Impact factor: 5.923

7.  Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia.

Authors:  Jae Seung Chung; Won Ik Seo; Cheol Kyu Oh; Seong Cheol Kim; Myung Chan Park; Sang Hyun Park; Jihyeong Yu; Chan Ho Lee; Wansuk Kim; Tae Yong Park; Kweon Sik Min; Jae Il Chung
Journal:  Investig Clin Urol       Date:  2019-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.